Sweden · Delayed Price · Currency is SEK Biosergen AB Statistics
Total Valuation
Biosergen AB has a market cap or net worth of SEK 99.10 million. The enterprise value is 83.73 million.
| Market Cap | 99.10M |
| Enterprise Value | 83.73M |
Important Dates
The next estimated earnings date is Tuesday, March 31, 2026.
| Earnings Date | Mar 31, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biosergen AB has 2.35 million shares outstanding. The number of shares has increased by 287.06% in one year.
| Current Share Class | 2.35M |
| Shares Outstanding | 2.35M |
| Shares Change (YoY) | +287.06% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 42.05% |
| Float | 850,731 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 47.46 |
| PB Ratio | 12.21 |
| P/TBV Ratio | 12.21 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.05 |
| EV / Sales | 40.10 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.95
| Current Ratio | 1.95 |
| Quick Ratio | 1.95 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -144.93% and return on invested capital (ROIC) is -90.67%.
| Return on Equity (ROE) | -144.93% |
| Return on Assets (ROA) | -68.46% |
| Return on Invested Capital (ROIC) | -90.67% |
| Return on Capital Employed (ROCE) | -389.70% |
| Weighted Average Cost of Capital (WACC) | 5.99% |
| Revenue Per Employee | 2.09M |
| Profits Per Employee | -40.82M |
| Employee Count | 1 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.66% in the last 52 weeks. The beta is 0.32, so Biosergen AB's price volatility has been lower than the market average.
| Beta (5Y) | 0.32 |
| 52-Week Price Change | -7.66% |
| 50-Day Moving Average | 43.23 |
| 200-Day Moving Average | 47.69 |
| Relative Strength Index (RSI) | 48.30 |
| Average Volume (20 Days) | 2,030 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Biosergen AB had revenue of SEK 2.09 million and -40.82 million in losses. Loss per share was -17.38.
| Revenue | 2.09M |
| Gross Profit | 2.09M |
| Operating Income | -40.86M |
| Pretax Income | -40.82M |
| Net Income | -40.82M |
| EBITDA | n/a |
| EBIT | -40.86M |
| Loss Per Share | -17.38 |
Balance Sheet
The company has 15.37 million in cash and n/a in debt, with a net cash position of 15.37 million or 6.54 per share.
| Cash & Cash Equivalents | 15.37M |
| Total Debt | n/a |
| Net Cash | 15.37M |
| Net Cash Per Share | 6.54 |
| Equity (Book Value) | 8.12M |
| Book Value Per Share | 3.46 |
| Working Capital | 10.48M |
Cash Flow
| Operating Cash Flow | -35.53M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -1,956.70% |
| Pretax Margin | -1,954.84% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Biosergen AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -287.06% |
| Shareholder Yield | -287.06% |
| Earnings Yield | -41.19% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 1, 2025. It was a reverse split with a ratio of 0.01.
| Last Split Date | Dec 1, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.01 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |